| Code | 9243E | ||||||||||
| MA number | 16/0073/25-S | ||||||||||
| Product Form: | cps dur 30x1x150 mg (blis.OPA/Al/PE//PE/Al/LDPE - jednotk.bal.) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | G.L. Pharma GmbH, Austria | ||||||||||
| Therapeutic Class: | 16 - ANTICOAGULANTIA (FIBRINOLYTICA, ANTIFIBRINOL.) | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 24 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 19.03.2025 |
| Validity: | 19.03.2030 |
| Pediatric indication: | Yes |
| Pediatric posology: | Yes |
| Pediatric contraindication: | Yes |
| Pediatric warnings: | Yes |
| PIL: |
PIL_Dabigatran-etexilát G.L. Pharma 150 mg tvrdé kapsuly_03.2025.pdf
|
| SPC: |
SPC_Dabigatran-etexilat G.L. Pharma 150 mg tvrdé kapsuly_03.2025.pdf
|
| Safety feature | Yes |
| Data update: | 21.03.2025 |
